TY - JOUR
T1 - Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients
AU - Hasson, Hamid
AU - Biswas, Priscilla
AU - Galli, Laura
AU - Burastero, Samuele E.
AU - Danise, Anna
AU - Bigoloni, Alba
AU - Carini, Elisabetta
AU - Locatelli, Massimo
AU - Vecchi, Andrea
AU - Lazzarin, Adriano
AU - Castagna, Antonella
PY - 2006/10
Y1 - 2006/10
N2 - Enfuvirtide (ENF) is the first HIV-1 entry inhibitor used in clinical practice and is currently administered via the subcutaneous route. We here evaluated whether ENF administration leads to a change in humoral parameters, including IgE, possibly related to ENF-associated injection site reactions (ISRs). A 24-week prospective study was conducted in multidrug resistant patients enrolled in the ENF Early Access Program characterized by CD4 counts ≤100 cells/microlitre and no other active antiretroviral drug. Licensed commercial laboratory assays were used to measure the parameters considered in this study. Results are reported as medians (interquartiles IQR). Statistical analyses were performed using Wilcoxon sign rank, Wilcoxon rank sum and Kruskall Wallis tests. Total IgM, IgA and IgG did not change significantly throughout the study. Conversely, a significant increase in IgE was observed in all patients, in those with normal as well as in those with altered IgE at baseline (BL). ISRs such as induration and number of nodules were more frequent in patients with altered BL IgE. IgE increased significantly in all patients, regardless of the different stratifications in their BL CD4 counts. Of note, the ENF-induced increase in CD4 occurred significantly in all patients, independently of their BL IgE levels. The immunological response associated with ENF treatment is accompanied by a selective increase in IgE levels. Determination of IgE could be used in the monitoring ISRs associated with ENF.
AB - Enfuvirtide (ENF) is the first HIV-1 entry inhibitor used in clinical practice and is currently administered via the subcutaneous route. We here evaluated whether ENF administration leads to a change in humoral parameters, including IgE, possibly related to ENF-associated injection site reactions (ISRs). A 24-week prospective study was conducted in multidrug resistant patients enrolled in the ENF Early Access Program characterized by CD4 counts ≤100 cells/microlitre and no other active antiretroviral drug. Licensed commercial laboratory assays were used to measure the parameters considered in this study. Results are reported as medians (interquartiles IQR). Statistical analyses were performed using Wilcoxon sign rank, Wilcoxon rank sum and Kruskall Wallis tests. Total IgM, IgA and IgG did not change significantly throughout the study. Conversely, a significant increase in IgE was observed in all patients, in those with normal as well as in those with altered IgE at baseline (BL). ISRs such as induration and number of nodules were more frequent in patients with altered BL IgE. IgE increased significantly in all patients, regardless of the different stratifications in their BL CD4 counts. Of note, the ENF-induced increase in CD4 occurred significantly in all patients, independently of their BL IgE levels. The immunological response associated with ENF treatment is accompanied by a selective increase in IgE levels. Determination of IgE could be used in the monitoring ISRs associated with ENF.
KW - CD4
KW - Enfuvirtide (ENF)
KW - IgE
KW - Immunological response
KW - Injection site reactions (ISRs)
UR - http://www.scopus.com/inward/record.url?scp=33845685254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845685254&partnerID=8YFLogxK
M3 - Article
C2 - 17201088
AN - SCOPUS:33845685254
VL - 29
SP - 223
EP - 230
JO - New Microbiologica
JF - New Microbiologica
SN - 1121-7138
IS - 4
ER -